Japan Nuclear Medicine Market to Reach USD 2.54 Billion by 2031 | Key Players Include GE Healthcare, Siemens Healthineers, Fujifilm Toyama Chemical, Canon Medical Systems, and Nihon Medi-Physics

The Japan Nuclear Medicine Market was valued at US$ 550.3 million in 2023 and is projected to reach US$ 2,543.2 million by 2031, growing at a CAGR of 21.2% during the forecast period 2024-2031.

The Japan Nuclear Medicine Market is growing due to increasing demand for precise diagnostic imaging and targeted therapeutic procedures. Market expansion is driven by technological advancements in radiopharmaceuticals, rising cancer incidence, and strong government support for healthcare innovation.

➠ Download Your Sample Report Instantly - Corporate Email ID Required for Priority Access: https://www.datamintelligence.com/download-sample/japan-nuclear-medicine-market?praneetha

Japan: Recent Industry Developments

✅ November 2025: Fujifilm Toyama Chemical Co., Ltd. announced the launch of a new radiopharmaceutical production facility in Tokyo to support the growing demand for diagnostic and therapeutic nuclear medicine. The facility integrates advanced automation systems to ensure precision and safety in isotope formulation. This expansion strengthens Japan's domestic supply chain for medical isotopes.

✅ October 2025: Canon Medical Systems Corporation introduced an advanced PET/CT imaging system designed for improved diagnostic accuracy in oncology and cardiology. The system features AI-powered image reconstruction and dose optimization technology, enhancing Japan's medical imaging capabilities.

✅ September 2025: Sumitomo Heavy Industries partnered with the National Institute of Radiological Sciences (NIRS) to develop next-generation cyclotron technology for efficient isotope production. The collaboration focuses on expanding access to short-lived radioisotopes used in nuclear diagnostics across Japan.

☛ Core Catalysts Behind Market Growth:

Rising prevalence of cancer and cardiovascular diseases is driving the demand for nuclear medicine in Japan for early diagnosis and targeted therapy.

Technological advancements in imaging modalities such as PET and SPECT are enhancing diagnostic accuracy and expanding clinical applications.

Increasing government support for healthcare innovation and investments in radiopharmaceutical research are accelerating market growth.

Growing adoption of personalized medicine and the development of novel radioisotopes are further strengthening Japan's position in the nuclear medicine market.

➠ Get Customization in the Report as per Your Requirements:
https://www.datamintelligence.com/customize/japan-nuclear-medicine-market?praneetha

☛ Market Segmentation:

By Product Type:
The market is categorized into Diagnostics and Therapeutics. Diagnostic nuclear medicine dominates due to the high demand for imaging technologies such as PET and SPECT for accurate detection of cardiovascular, oncological, and neurological disorders. Therapeutic nuclear medicine is growing rapidly, driven by advancements in targeted radiopharmaceuticals for cancer and thyroid treatments.

By Procedural Volume Assessment:
Segments include Diagnostic Procedures and Therapeutic Procedures. Diagnostic procedures hold a major share due to the widespread adoption of non-invasive imaging for early disease detection and monitoring. Therapeutic procedures are increasing in volume with the growing use of radionuclide therapy in oncology and endocrinology.

By Application:
Applications include Cardiology, Oncology, Neurology, Thyroid Disorders, EndocrineTumors, Lymphoma and Bone Metastasis, Pulmonary Scans, Urology, and Others. Oncology leads the market owing to the growing prevalence of cancer and increasing use of radiopharmaceuticals for tumor imaging and therapy. Cardiology and neurology applications follow, supported by the need for accurate diagnosis of heart diseases and brain disorders. Thyroid disorders and endocrine tumors are expanding areas due to increased use of radioactive iodine and peptide-based therapies.

By End-User:
The market is divided into Hospitals, Diagnostic Centers, and Others. Hospitals dominate the market due to the availability of advanced imaging equipment and specialized nuclear medicine departments. Diagnostic centers are growing steadily with increased outsourcing of imaging procedures and the rise in independent radiology facilities across Japan.

☛ Competitive Landscape:

GE Healthcare - A global leader in nuclear medicine imaging and radiopharmaceutical solutions, offering advanced PET and SPECT systems that enhance diagnostic precision and clinical workflow efficiency.

Siemens Healthineers - Provides cutting-edge molecular imaging technologies and radiopharmaceutical production solutions, supporting early disease detection and personalized treatment planning.

Fujifilm (FUJIFILM Toyama Chemical Co. Ltd) - Focuses on developing innovative diagnostic radiopharmaceuticals and imaging agents to strengthen Japan's nuclear medicine capabilities.

Nihon Medi-Physics Co. (Sumitomo Chemical Co. Ltd) - A key domestic manufacturer of radiopharmaceuticals, contributing to Japan's supply chain stability and advancements in diagnostic imaging.

CANON MEDICAL SYSTEMS CORPORATION - Offers state-of-the-art nuclear imaging equipment and hybrid imaging systems designed to deliver high-quality diagnostic insights with reduced radiation exposure.

➠ Purchase this report before year-end and unlock an exclusive 30% discount:

Buy Now & Unlock 360° Market Intelligence:
https://www.datamintelligence.com/buy-now-page?report=japan-nuclear-medicine-market?praneetha
(Purchase 2 or more Reports and get 50% Discount)

☛ Regional Analysis:

Japan: The nuclear medicine market in Japan is growing steadily, supported by advanced healthcare infrastructure, strong government backing for diagnostic imaging, and increasing prevalence of cancer and cardiovascular diseases. The country's leading role in technological innovation and radiopharmaceutical production, with companies like Fujifilm, Nihon Medi-Physics, and Canon Medical Systems, strengthens market growth. Rising adoption of PET and SPECT imaging systems, along with ongoing investments in research and development, continues to drive the expansion of Japan's nuclear medicine sector.

➠ Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.
✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Market Access Snapshots
✅ Emerging Risks & Market Volatility Analysis
✅ Quarterly Updated Reports
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

☛ Related Reports:

Nuclear Medicine Radioisotopes Market: https://www.datamintelligence.com/research-report/nuclear-medicine-radioisotopes-market?praneetha

Nuclear Imaging Equipment Market: https://www.datamintelligence.com/research-report/nuclear-imaging-equipment-market?praneetha

Nuclear Imaging Market : https://www.datamintelligence.com/research-report/nuclear-imaging-market?praneetha

Company Name: DataM Intelligence 4Market Research LLP
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com/

DataM Intelligence is a global Market Research and Consulting firm providing comprehensive business insights and end-to-end solutions from research to consulting. We deliver actionable intelligence across 6,300+ reports spanning 40+ domains, empowering over 200 companies in 50+ countries. Our focus is on enabling clients to make data-driven decisions through robust methodologies, strategic foresight, and real-time market intelligence.

This release was published on openPR.